Skip to main content
Fig. 6 | Acta Neuropathologica Communications

Fig. 6

From: Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease

Fig. 6

LRRK2 mutation carriers have AD-type tau pathology. a The log value of AT8 and GT-38 pathology for each region is plotted as a scatterplot, with different diseases or genotypes represented by different colors. Linear regression best-fit lines are shown in the same colors. AD and LRRK2 mutation carriers all show high correlation between AT8 and GT-38 values (AD: R2adj = 0.82, p = 0.002946; LRRK2 mutation: R2adj = 0.70, p < 2.20e-16), suggesting that the predominant tau form is AD tau. In contrast, AT8 and GT-38 values show no correlation in CBD, Pick’s and PSP cases, resulting in segregation of these regions from LRRK2 mutation carriers and AD cases (CBD: R2adj = − 0.11, p = 0.5137; Pick’s: R2adj = − 0.16, p = 0.6037; PSP: R2adj = − 0.22, p = 0.7743). b The same regional AT8 and GT-38 pathology values as in panel (a) are plotted here, but with each different case plotted as a different color and with linear regression done on each case independently. All but one of the LRRK2 mutation carriers overlays nicely, suggesting that each case independently has AD tau. The one exception, p.G2019S-1 has very minimal tau pathology and therefore cannot be described as having AD tau

Back to article page
\